CDA | Evidence Driven
CDA | Evidence Driven

durvalumab, tremelimumab

Details

Files
Generic Name:
durvalumab, tremelimumab
Project Status:
Active
Therapeutic Area:
Metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi, Imjudo
Project Line:
Reimbursement Review
Project Number:
PC0390-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open05-Sep-24
Call for patient/clinician input closed28-Oct-24
Submission received17-Oct-24
Submission accepted31-Oct-24
Review initiated01-Nov-24
Draft CADTH review report(s) provided to sponsor for comment23-Jan-25
Deadline for sponsors comments04-Feb-25
CADTH review report(s) and responses to comments provided to sponsor28-Feb-25
Expert committee meeting (initial)12-Mar-25
Draft recommendation issued to sponsorMarch 25, 2025
To
March 27, 2025
Draft recommendation posted for stakeholder feedback03-Apr-25
End of feedback period17-Apr-25

Files

Patient and Clinician Group input View PDF
Last Updated : November 21, 2024